"Completely Beyond The Pale..."

Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts. Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That compares with 18,410 prescriptions for Novo's oral version of Wegovy during its second week after launch, suggesting Lilly's weight-loss drugs are falling behind...

"Now Taking Reservations For 2031 Delivery": GE Vernova Gas Turbine Backlog Climbs To 116 GW By Brian Martucci of UtilityDive GE Vernova posted double-digit revenue and order growth in the second quarter, driven once again by continued strong performance in its Power and Electrification business segments. Those segments, respectively, produce and service gas, hydro and nuclear power generation equipment; and commercial electrical equipment such as transformers and switchgears. GE Vernova’s beleaguered third segment, Wind, saw orders fall sharply amid persistent softness in U.S. demand for onshore wind turbines and blades. “We remain focused...

"This Is Huge!": Trump Hails Ibogaine Application Gift Aimed At Helping Veterans With Mental Illness Authored by Kimberley Hayek via The Epoch Times, President Donald Trump said that the University of Miami has given its original 1994 investigational new drug application for ibogaine to the federal government, a move he said would accelerate development of the psychedelic substance as a treatment for serious mental illness. The gift aims to speed work on the substance as a possible treatment for serious mental illness suffered by veterans. The 1994 application was the original filing that...